Entrar/Registro  
INICIO ENGLISH
 
Revista de Investigación Clínica
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Revista de Investigación Clínica >Año 2009, No. 3


Selman M, Mejía M, Pardo A
Fibrosis pulmonar idiopática
Rev Invest Clin 2009; 61 (3)

Idioma: Español
Referencias bibliográficas: 52
Paginas: 233-242
Archivo PDF: 181.12 Kb.

[Texto completo - PDF]

FRAGMENTO

Masculino de 60 años, exfumador (tabaquismo por espacio de 10 años consumiendo 10 cigarros al día, el cual suspendió hace 30 años). Sin antecedentes heredofamiliares ni personales de importancia. Sin evidencia de exposición laboral o ambiental con excepción del tabaquismo.


Palabras clave: Sin palabras Clave


REFERENCIAS

  1. King TE Jr. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med 2005; 172: 268-79.

  2. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810-6.

  3. Olson AL, Swigris JJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007; 176: 277-84.

  4. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-81.

  5. Pisano S, Galati A, Cacchione S. Telomeric nucleosomes: Forgotten players at chromosome ends. Cell Mol Life Sci 2008 [Epub ahead of print].

  6. Shawi M, Autexier C. Telomerase, senescence and ageing. Mech Ageing Dev 2008; 129: 3-10.

  7. Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev 2008; 88: 557-79.

  8. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356: 1317-26.

  9. Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007; 104: 7552-7.

  10. Loyd JE. Pulmonary fibrosis in families. Am J Respir Cell Mol Biol 2003; 29(Suppl. 3): S47-S50.

  11. Cronkhite JT, Xing C, Raghu G, et al. Telomere Shortening in Familial and Sporadic Pulmonary Fibrosis. Am J Respir Crit Care Med 2008; 178(7): 729-37.

  12. Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 2008; 105: 13051-6.

  13. Gotway MB, Freemer MM, King TE Jr. Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias. Thorax 2007; 62: 546-53.

  14. Katzenstein AL, Mukhopadhyay S, Myers JL. Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Hum Pathol 2008; 39: 1275-94.

  15. Noth I, Martinez FJ. Recent advances in idiopathic pulmonary fibrosis. Chest 2007; 132: 637-50.

  16. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment; international consensus statement. Am J Respir Crit Care Med 2000; 161: 646-64.

  17. Martinez, FJ, Safrin S, Weycker, D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Int Med 2005; 142: 963-7.

  18. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS ONE 2007; 2(5): e482.

  19. Collard HR, Moore BB, Flaherty KR, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636-43.

  20. Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26: 586-93.

  21. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-51.

  22. Pardo A, Selman M. Molecular mechanisms of pulmonary fibrosis. Front Biosci 2002; 7: d1743-d761.

  23. Pardo A, Selman M. Idiopathic pulmonary fibrosis: new insights in its pathogenesis. Int J Biochem Cell Biol 2002; 34: 1534-8.

  24. Zuo F, Kaminski N, Eugui E, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002; 99: 6292-7.

  25. Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc 2006; 3: 293-8.

  26. Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005; 172: 1146-52.

  27. Stewart JP, Egan JJ, Ross AJ, et al. The detection of Epstein- Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1999; 159: 1336-41.

  28. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 27: 136-42.

  29. D’Ovidio F, Singer LG, Hadjiliadis D, et al. Prevalence of gastroesophageal reflux in end-stage lung disease candidates for lung transplant. Ann Thorac Surg 2005; 80: 1254-60.

  30. Grutters JC, du Bois RM. Genetics of fibrosing lung diseases. Eur Respir J 2005; 25: 915-27.

  31. Pardo A, Gibson K, Cisneros J, et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2005; 2: e251.

  32. Selman M, Thannickal VJ, Pardo A, et al. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 2004; 64: 405-30.

  33. Andersson-Sjöland A, de Alba CG, Nihlberg K, et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008; 40: 2129-40.

  34. Cosgrove GP, Brown KK, Schiemann WP, et al. Pigment epithelium- derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 2004; 170: 242-51.

  35. Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995; 77: 493-504.

  36. Pan T, Mason RJ, Westcott JY, Shannon JM. Rat alveolar type II cells inhibit lung fibroblast proliferation in vitro. Am J Respir Cell Mol Biol 2001; 25: 353-61.

  37. Lama V, Moore BB, Christensen P, Toews GB, Peters-Golden M. Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2- dependent. Am J Respir Cell Mol Biol 2002; 27: 752-8.

  38. Kohyama T, Ertl R, Valenti V, et al. Prostaglandin E2 inhibits fibroblast chemotaxis. Am J Physiol 2001; 281: L1257- L1263.

  39. Petkova DK, Clelland CA, Ronan JE, Lewis S, Knox AJ. Reduced expression of cyclooxygenase (COX) in idiopathic pulmonary fibrosis and sarcoidosis. Histopathology 2003; 43: 381-6.

  40. Xaubet A, Roca-Ferrer J, Pujols L, et al. Cyclooxygenase-2 is up-regulated in lung parenchyma of chronic obstructive pulmonary disease and down-regulated in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 35-42.

  41. Willis BC, Liebler JM, Luby-Phelps K, et al. Induction of epithelial- mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005; 166: 1321-32.

  42. Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006; 103: 13180-5.

  43. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131-42.

  44. Moustakas A, Heldin CH. Signaling networks guiding epithelial- mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 2007; 98: 1512-20.

  45. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764-74.

  46. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial- mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17: 548-58.

  47. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006; 66: 8319-26.

  48. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelialmesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-81.

  49. Iwano M, Plieth D, Danoff TM, et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341-50.

  50. Chaffer CL, Brennan JP, Slavin JL, et al. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006; 66: 11271-8.

  51. Zeisberg M, Yang C, Martino M, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007; 282: 23337-47.

  52. Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med 2008; 5(3): e62.



>Revistas >Revista de Investigación Clínica >Año2009, No. 3
 

· Indice de Publicaciones 
· ligas de Interes 
       
Derechos Resevados 2007